HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benzoyl peroxide warning to avoid "unnecessary sun exposure" proposed by FDA.

This article was originally published in The Rose Sheet

Executive Summary

BENZOYL PEROXIDE LABEL WARNING TO AVOID "UNNECESSARY SUN EXPOSURE" is recommended by FDA in a Feb. 17 notice of proposed rulemaking establishing additional labeling for all topically applied acne treatment drug products containing benzoyl peroxide. FDA has tentatively determined that because "some harm may result from exposure to sunlight in conjunction with the use" of benzoyl peroxide products, "consumers who use products containing this ingredient need to be informed about an additional condition related to this use, i.e., to avoid unnecessary sun exposure and to use a sunscreen," the Federal Register notice states.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel